ACOUSORT AB

Their core work

Acousort AB is a Swedish deep-tech SME that develops acoustophoresis-based microfluidic systems — technology that uses acoustic wave forces to precisely sort, separate, and manipulate biological particles such as cells and blood plasma. Their core commercial application is point-of-care diagnostics, specifically enabling rapid blood plasma separation without conventional laboratory infrastructure. In H2020 projects they contributed acoustophoresis expertise both as a specialist participant in fundamental FET materials research (BioWings) and as the lead of a commercial-stage SME Instrument project (ACOUPLASMA), demonstrating capability across the full research-to-market arc. They are based in Lund, Sweden, a recognized European hub for acoustofluidics science.

What they specialise in

How they've shifted over time

Both H2020 projects launched in 2018, which makes multi-year keyword drift analysis impossible — there is simply no later-period keyword data to contrast against the early set of acoustophoresis, Bio-MEMS, and electrostriction. What the dual-project structure does reveal is that Acousort ran a deep research track (BioWings, FET-RIA, 2018-2022) and a commercialization track (ACOUPLASMA, SME Instrument Phase 1, 2018-2019) simultaneously from the start of their EU project history. This is less an evolution and more a deliberate dual-speed strategy: stay connected to frontier science while driving product development in parallel.

With one FET research participation and one self-led SME commercialization project both beginning in 2018, Acousort points clearly toward medical device commercialization — a company that uses research consortia to validate technology while independently pushing acoustic separation products toward the market.

How they like to work

Acousort occupies both ends of the project leadership spectrum: they coordinated a fast-cycle SME Instrument Phase 1 project (ACOUPLASMA) and joined a larger FET-RIA consortium as a specialist contributor (BioWings). With just 6 unique partners across 5 countries in their entire H2020 history, their network is intentionally selective — they do not appear to pursue large multi-partner consortia. This pattern suggests they engage as focused technology providers of acoustophoresis capability rather than as broad consortium builders.

Acousort has worked with 6 unique partners across 5 countries — a modest but internationally distributed footprint for a 2-project SME. The cross-country reach in a small portfolio indicates willingness to collaborate beyond Sweden, though their overall network remains limited in scale.

What sets them apart

Acousort occupies a rare niche: a commercially-oriented SME with hands-on product experience in acoustophoresis, a precision particle separation method that most organizations encounter only in academic literature. They bring the unusual combination of FET-level research credibility (through BioWings) and demonstrated SME project leadership (ACOUPLASMA), which makes them a credible partner at any stage from TRL 3 to TRL 7. For a consortium building around microfluidic diagnostics, lab-on-chip, or acoustic bioseparation, they offer both technical depth and product orientation that is rare in a company of their size.

Highlights from their portfolio

• BioWings
  The largest funded project (EUR 179,937) placed Acousort inside a FET Research and Innovation Action on bio-compatible electrostrictive smart materials, validating their acoustophoresis technology as relevant to fundamental frontier research alongside academic consortia.
• ACOUPLASMA
  As coordinator of this SME Instrument Phase 1 project, Acousort demonstrated independent project leadership with a direct commercial objective — market maturation of their acoustic blood plasma separation module for point-of-care diagnostics.